

Caffeine citrate

Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)

Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)

Indications

Apnoea of newborn

Carbetocin

Section

Uterotonics

Parenteral > General injections > IV: 100 µg per mL (heat stable)

Indications

Postpartum haemorrhage

Chlorhexidine

Section

Medicines administered to the neonate [c]

Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)

Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)

Indications

Omphalitis of newborn

Clomifene

Section

Ovulation inducers

Oral > Solid: 50 mg (citrate)

Indications

Female infertility without specification whether primary or secondary

Condoms

Section

Barrier methods

-

Indications

Contact with health services for contraceptive management

Copper-containing intrauterine device

Section

Intrauterine devices

-

Indications

Contact with health services for insertion of contraceptive device

Dexamethasone

Section	Indications
Other medicines administered to the mother Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))	Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

Diaphragms

Section	Indications
Barrier methods -	Contact with health services for contraceptive management

Ergometrine

Section	Indications
Uterotonics Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)	Postpartum haemorrhage

Estradiol cypionate + medroxyprogesterone acetate

Section	Indications
Injectable hormonal contraceptives Parenteral > General injections > IM: 5 mg + 25 mg	Contact with health services for reasons associated with reproduction

Ethinylestradiol + etonogestrel

Section	Indications
Intravaginal contraceptives Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg	Contact with health services for contraceptive management

Ethinylestradiol + levonorgestrel

Section	Indications
Oral hormonal contraceptives Oral > Solid: 50 µg + 250 µg [4] Oral > Solid: 30 µg + 150 µg	Contact with health services for postcoital contraception Contact with health services for contraceptive management

Ethinylestradiol + norethisterone

Section

Oral hormonal contraceptives

Oral > Solid: 35 µg + 1 mg

Indications

Contact with health services for contraceptive management

Etonogestrel-releasing implant

Section

Implantable contraceptives

Implant > Subdermal: 68 mg single rod

Indications

Contact with health services for insertion of contraceptive device

Ibuprofen

Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 5 mg per mL

Indications

Patent arterial duct

Indometacin

Section

Medicines administered to the neonate [c]

Indications

Therapeutic equivalent to [ibuprofen](#) pour

Patent arterial duct

Letrozole

Section

Ovulation inducers

Oral > Solid > dosage form: 2.5 mg

Indications

Female infertility without specification whether primary or secondary

Levonorgestrel

Section

Oral hormonal contraceptives

Oral > Solid: 750 µg [2]; 1.5 mg [1]

Oral > Solid: 30 µg

Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Intrauterine devices

Intrauterine system with reservoir containing 52 mg of levonorgestrel.

Contact with health services for insertion of contraceptive device

Levonorgestrel-releasing implant

Section

Implantable contraceptives

Implant > Subdermal: 75 mg per rod (two-rods)

Indications

Contact with health services for insertion of contraceptive device

Medroxyprogesterone acetate

Section

Injectable hormonal contraceptives

Parenteral > General injections > IM: 150 mg per mL in 1 mL vial

Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system

Indications

Contact with health services for reasons associated with reproduction

Methylergometrine

Section

Uterotonics

Indications

Therapeutic equivalent to *ergometrine* pour

Postpartum haemorrhage

Mifepristone - misoprostol

Section

Uterotonics

Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package

Indications

Induced abortion

Unspecified time of fetal death, cause not specified

Misoprostol

Section

Uterotonics

Oral > Solid: 200 µg

Local > Vaginal > tablet: 25 µg

Indications

Spontaneous abortion, incomplete, without complication

Unspecified obstetric condition

Postpartum haemorrhage

Multiple micronutrient supplement

Section	Indications
Other medicines administered to the mother Tablet containing: Vit A: 800 mcg retinol activity equivalent Vit C: 70 mg Vit D: 5 mcg (200 IU) Vit E: 10 mg alpha tocopherol equivalent Vit B1: 1.4 mg Vit B2: 1.4 mg Vit B3: 18 mg niacin equivalent Vit B6: 1.9 mg Folic acid: 400 mcg Vit B12: 2.6 mcg Iron: 30 mg Iodine: 150 mcg Zinc: 15 mg Selenium: 65 mcg Copper: 2 mg	Maternal care for other specified conditions predominantly related to pregnancy

Nifedipine

Section	Indications
Antioxytotics (tocolytics) Oral > Solid: 10 mg (immediate-release)	Preterm labour without delivery

Norethisterone

Section	Indications
Oral hormonal contraceptives Oral > Solid: 350 µg	Contact with health services for contraceptive management

Norethisterone enantate

Section	Indications
Injectable hormonal contraceptives Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution	Contact with health services for reasons associated with reproduction

Oxytocin

Section	Indications
Uterotonics Parenteral > General injections > unspecified: 10 IU per mL	Postpartum haemorrhage

Progesterone vaginal ring

Section	Indications
Intravaginal contraceptives Local > Vaginal > vaginal ring: 2.074 g micronized progesterone	Contact with health services for contraceptive management

Prostaglandin E1

Section	Indications
Medicines administered to the neonate [c] Parenteral > General injections > IV: 0.5 mg per mL in alcohol	Other specified congenital anomaly of great arteries including arterial duct

Prostaglandin E2

Section	Indications
Medicines administered to the neonate [c] Parenteral > General injections > IV: 1 mg per mL	Therapeutic equivalent to prostaglandin E1 pour Other specified congenital anomaly of great arteries including arterial duct Other specified congenital anomaly of great arteries including arterial duct

Surfactant

Section	Indications
Medicines administered to the neonate [c] Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation	Respiratory distress syndrome of newborn

Tranexamic acid

Section	Indications
Other medicines administered to the mother Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Postpartum haemorrhage

Ulipristal

Section

Oral hormonal contraceptives

Oral > Solid: 30 mg tablet (ulipristal acetate)

Indications

Contact with health services for postcoital contraception